We read with interest the article[@ref1] depicting the use of prostate-specific antigen (PSA) as a diagnostic tool in polycystic ovarian disease. While serum PSA levels in females are much lower than in males, and often need ultrasensitive immunoassays for quantification,[@ref2] their importance cannot be overlooked. Indeed, PSA has come up as a potential serological diagnostic and prognostic tool in women recently. Increased levels of serum PSA has been detected in women with breast cysts and fibroadenoma[@ref3] and is also thought to be a prognostic marker in women with metastatic breast cancer treated with megestrol acetate.[@ref4] However, the levels of PSA in malignant breast tissue have been found to be lower than in normal breast tissue or benign hyperplasia.[@ref5] The value of PSA also increases in carcinoma of the female prostate (Skene\'s gland).[@ref6] PSA has been detected in amniotic fluids[@ref7] with the levels varying with gestational age and hence it has been suggested as a candidate growth factor.[@ref7][@ref8]

Thus, while much remains to be known about the biology of the physiological function of PSA in females, evidence indicates that it may emerge as a robust serological tool in near future for diagnosis and prognosis of many disorders.
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